Sept 11 (Reuters) - The U.S. Food and Drug Administration's staff on

Wednesday raised efficacy concerns over Intercept Pharmaceuticals' liver disease

drug, which is awaiting traditional approval.

The reviewers, in briefing documents published on the FDA's website,

said the confirmatory trial for the drug did not provide evidence that it was

effective in patients with a rare condition called primary biliary cholangitis

(PBC).